Skip to Content

About Us

Therapeutics / Biologics

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.


MDA10-104
Infectivity-Enhanced Conditionally-Replicative Adenovirus and Uses Thereof
Please contact the office for more information on this technology.


MDA10-079
Targeting Soluble Protein Aggregates for Diagnosis, Treatment and Prevention of Autoimmune Diseases and Amyloidosis
Please contact the office for more information on this technology.


MDA10-069
Transglutaminase 2 (TG2)-Induced EMT and Stem Cell Like Characteristics as Therapeutic Target
Please contact the office for more information on this technology.


MDA10-061
Targeting Jagged1
Please contact the office for more information on this technology.


MDA10-057
Intelligent BioMarkers (I-biomarkers) in Bladder Cancer
Please contact the office for more information on this technology.


MDA10-045
Tumor Targeted Delivery of Immunomodulators by Nanopolymers
Please contact the office for more information on this technology.


MDA10-003
Role of CAMK-III Kinase (eEF2 Kinase) in Cancer
Please contact the office for more information on this technology.


MDA09-077
IL-21 muteins for lymphocyte propagation
Please contact the office for more information on this technology.


MDA09-036
Discovery of a Functional Protein Complex of Netrin-4, Laminin y1 Chain, and Integrin a6b1 in Mouse Neural Stem Cells
Please contact the office for more information on this technology.


MDA09-029
miR-200 Use to Reverse EGFR Resistance in Bladder Cancer or to Identify the Responders to EGFR Therapy
Please contact the office for more information on this technology.


MDA09-014
Monoclonal Antibody to the Combined Epitope of PR1 Plus HLA-A*0201
Please contact the office for more information on this technology.


MDA09-007
Preparation and Methodology of Silk Fibroin-derived Therapeutic Nanoparticles
WO/2010/059963


MDA08-147
Peptides That Bind Eukaryotic Translation Initiation Factor 4E
Please contact the office for more information on this technology.


MDA08-142
Tumor Targeting siRNA Nanovectors for Treatment of Primary and Metastatic Cancers
Please contact the office for more information on this technology.


MDA08-118
Tumor Targeting siRNA Nanovectors for Treatment of Cancer
Please contact the office for more information on this technology.


MDA08-116
Modulation of Follicular Helper T Cells, a Novel Subset of T Cells
WO2010/003002


MDA08-107
Therapeutic Targeting of SRC Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.


MDA08-096
Using Recombinant Bone Marrow Stromal Antigen-2 to Treat Autoimmune Diseases
WO/2010/065536


MDA08-084
Therapeutic Targeting of Paxillin Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.


MDA08-078
Therapeutic ATP7B siRNA
Please contact the office for more information on this technology.


MDA08-069
Therapeutic Targeting of the Thrombin Receptor (PAR-1) Using SiRNA in Neutral Liposomes (DOPC)
Please contact the office for more information on this technology.


MDA08-056
PR1 Target Antigen in Human Breast Cancer
WO2009/102909


MDA08-031
In Vivo Delivery of Nucleic Acids with Nanoparticles
WO/2010/057203


MDA08-029
Therapeutic Targeting of EphB4 Using siRNA in Neutral Liposomes
Please contact the office for more information on this technology.


MDA07-104
Peptides Competing with CD74-Fas Complex Enhance Cancer Cell Apoptosis
WO 2009/014702
US-2010-0266577-A1


MDA07-091
IL-21 as a Novel Target in Inflammatory Diseases
WO2008/150885


MDA07-087
Dickkopf-1 (DKK1) as a Universal Tumor Vaccine for Immunotherapy of Cancers.
WO/2008/144659


MDA07-067
Therapeutic Targeting of Interleukin-8 (IL-8) Using siRNA in Neutral Liposomes (DOPC)
WO/2008/109432
US2010-0172962


MDA07-060
RAGE Inhibitor Peptides
WO/2008/154638
US-2010-0249038-A1


MDA07-057
Elimination of Cancer Stem Cells by Immunotherapy Targeting Notch and Numb
WO 2008/108910
US-2010-0062012


MDA07-056
Therapeutic Targeting of Prefoldin 4 (PFDN4) Using siRNA in Neutral Liposomes
WO2008/100922


MDA07-036
Cancer Specific Promoters
US-2009-0192101-A1
WO 2008/070448


MDA07-023
Antibodies for the Treatment and Prevention of Psoriasis
WO/2008/076981


MDA07-018
CD44-Targeted Paclitaxel Copolymer Prodrug (HA-TXL)
WO/2008/134528
US2010-0173865


MDA07-016
TG2 as Target for Treating Pancreatic Ductal Adenocarcinoma
US 2008/0279844
WO 2008/063760


MDA06-097
A Signaling Deficient Reporter for Imaging Gene Expression and Following Cell Trafficking/Function/(trans)Differentiation
WO2008/085564


MDA06-079
Notch Agonists as a Novel Therapeutic Approach to B Cell and Myeloid Leukemias
Please contact the office for more information on this technology.


MDA06-018
Inhibition the Generation of IL-10 Producing OX-40 Receptor
US 2008-0286286 A1
WO2007/084559


MDA06-013
Utility of the Zinc Finger Protein 306 in the Diagnostic and Therapeutics of Colorectal Cancer
US 2007-0298445 A1
WO/2007/103876


MDA05-134
Compositions and Methods for the Direct Therapy of Tumors
US-2007-0196277-A1
WO2007/085026


MDA05-125
Methods to Treat Cancer
US2007-0243191 A1
WO/2008/054431


MDA05-086
A Method of Generating Blood Elements from Non-Hematopoietic Tissue
WO2007/016037


MDA05-068
Oncogenic Ras-specific Cytotoxic Compound and Methods of Use Thereof
WO2007/062399
US-2009-0286847-A1


MDA05-003
Liposomal Small Interference RNA (siRNA)
WO2006/113679
US-2009-0012021-A1


MDA04-083
Raman Activated Cell Sorting
US-2010-0291537-A1
WO 2006/060171


MDA04-053
Identification of DeltaDNMT3Bs and Their Role in Regulation of Promoter-Specific Methylation in Tumorigenesis
7,405,287


MDA04-043
A Mutation in KIT Confer Imatinib Resistance in GISTs
7,329,495
Please contact the office for more information on this technology.


MDA04-017
Breast Cancer Specific Promoter
7,816,131
WO/2005/103251
7,723,104


MDA03-037
JAB1 as a Prognostic Marker and a Therapeutic Target for Human Cancer
US2009-0148868


MDA03-021
Chronic Myeloid Leukemia Cells Secrete a Proapoptotic Factor Mediating Cell Death of Normal Bone Marrow Cells but not Leukemic Cells
WO 2006/086638
US2008-0274104


MDA03-005
Anti-tumor Effect of Mutant Bik Gene
US-2005-0118154-A1
WO2004/089981
US-2009-0075885


MDA03-004
Active Specific Immunotherapy of Brain Metastasis by Lyophilized Insect Cells Producing Interferon-beta
US 2006-0228326 A1
WO2004/037182


MDA02-087
Endostatin and Angiostatin as Targeting Proteins to Deliver Therapeutic or Diagnostic Reagent
US-2004-0005684-A1
WO/2003/093303
US-2007-0134206-A1


MDA01-049
Induction of Tumor Immunity by Controlled Modification of Amino Acid Side Chain Length Using Methyl/Methylene (CH2/CH3)
US 2005-0169934 A1
WO/2003/076585


MDA01-037
Inhibition of Angiogenesis, Tumor Growth and Metastasis by Fully Human Anti-IL8 (ABX-IL8) in Diverse Types of Tumors
US-2003-0068319-A1
7,067,131
6,924,360
7,090,844
US-2006-0246077-A1
WO/2002/077172
WO/2003/057838
WO/2003/057837
WO/2003/057006


MDA00-056
WWOX - a Putative Tumor Suppressor Gene Mutated in Multiple Cancers
7,060,811


MDA00-043
Induction of Tumor Immunity by Variants of FBP
7,547,759


MDA00-020
Baculovirus Expressed Interferon Beta Compositions for Inhibiting Primary and Metastatic Cancer
6,872,385
WO01/92484A2


MDA00-017
Discovery of a Novel Candidate Tumor Suppressor Gene CAR-1
6,943,245
7,169,384
WO01/12285


MDA00-009
Isolation of a Peptide for Potential Drug Delivery into Human Head and Neck and Other Solid Tumors
6,919,425
US 2006-0188437 A1
WO02/02147A2


MDA00-004
Fabrication of Biodegradable Microspheres as Carriers for Bioactive Proteins Using a Solid Encapsulation/Single Emulsion/Solvent Extraction Technique
6,962,716
7,291,348


MDA99-042
C-CAM as an Angiogenesis Inhibitor
6,517,828
WO00/73340


MDA97-044
Lipid-Carrier Protein Conjugates - Induction of Autoimmunity for Immunotherapy of Cancer
6,300,308
6,806,354
7,563,446
WO99/33522


MDA97-036
HIV Peptides for CTL Induction
6,656,471
7,306,804
WO/2000/029008


MDA97-031
NOE-Y2, A Novel Tumor Suppressor Gene in Ovarian and Breast Carcinomas
7,183,401
WO98/42830


MDA96-053
Cloning of an Osteoblast Specific Transcription Factor
6,518,063
WO98/54322


MDA96-012
Sensitization Of HER-2/neu Overexpressing Cancer Cells To Chemotherapeutic Agents By Adenovirus 5 E1A
6,395,712
7,005,424
WO97/35012


MDA94-022
Cancer Therapies by HER-2 Peptides
6,514,942
US-2003-0027766-A1


MDA92-014
Inhibition of Nitric-Oxide Mediated Hypotension and Septic Shock with Iron-Containing Hemoprotein
5,296,466
5,480,866
5,674,836
5,900,403
6,103,690
6,350,729
WO/1993/016721

For More Information


© 2014 The University of Texas MD Anderson Cancer Center